Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection

HERZLIYA, Israel and CALGARY, AB, Sept. 18, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce its ongoing collaboration with Freedom Farm, a sanctuary dedicated to rescuing animals that were expelled from the industrial farms as a result of the animals having physical disabilities and other medical conditions. Through this collaboration, Freedom Farm animals that suffer from painful conditions receive compassionate care supported by Innocan's advanced long-acting injectable LPT-CBD analgesic, to help alleviate their pain and significantly improve their well-being.

Among the many animals saved by Freedom Farm, Billy and Dror stand out. Two goats that arrived at the farm with severe skeletal and joint deformities endure chronic pain that makes daily activities and social interaction extremely difficult.

For the past two years, these goats have received compassionate treatment with Innocan's LPT-CBD delivered through a single subcutaneous injection every 6–9 weeks. The treatment was observed to significantly reduce their pain, restore their mobility, and allow them to play and socialize with their animal friends — a transformation that speaks to the profound impact of LPT-CBD. Moreover, no adverse events were noticed, even after such a long period of repeated treatment.

Animals suffering from severe conditions that limit them from performing daily activities and basic functions are often euthanized. Thanks to Innocan's LPT-CBD compassionate care, Billy and Dror regained mobility and social interaction — greatly enhancing their quality of life.

LPT-CBD is a liposomal drug product designed to treat chronic pain through a prolonged release mechanism of synthetic CBD.

Meital Ben Ari, Co-Founder of Freedom Farm stated, "The life of Billy and Dror were completely transformed after engaging with LPT-CBD treatment". "It was clearly visible. The pain caused by their severe disabilities has been significantly alleviated. For two years now, the two have been enjoying their lives, have a good appetite, and are cheerful. To me, this is almost a miracle".

"This initiative reflects our commitment to making a meaningful and sustainable impact not only on the health of companion and farm animals, but also by inspiring a more compassionate world through nurturing the bond between humans and animals", said Iris Bincovich the Chief Executive Officer of Innocan Pharma. "Seeing animals like Billy and Dror regain quality of life is a true reflection of how our science can make a meaningful difference."

Eyal Kalo, Vise President of Research and Development added "The clinical feedback from this compassionate case provides strong support for the long-lasting pain relief and tolerability achieved with LPT-CBD. Together with the extensive pre-clinical data gathered over the years, these results further highlight the significant potential of our technology to transform pain management in animals and humans.

About Innocan
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary. www.innocanpharma.com

For further information, please contact:
Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. For example, the Company is using forward-looking statements when it discusses the potential of the Company's LPT-CBD technology as an innovative solution for pain management in patients. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg